Thomas Luginbill knows what it takes to be a successful entrepreneur. He spearheaded the founding of a campus organization when he was an undergraduate, helped start a family-run contracting business and co-created a start-up technology venture while studying for an MBA. This self-described "serial entrepreneur" has been named as director of the College of Southern Maryland's newly formed Entrepreneur and Innovation Institute (EII).


With concerns over a continued Zika outbreak growing, the Food and Drug Administration has given Roche Holdings emergency approval to use one of its Zika blood testing kits.

The approval, which lasts as long as the emergency is ongoing, will allow for testing of the virus through Roche's LightMix Zika rRT-PCR test, which has not been approved by the FDA yet.


Eli Lilly ($LLY) has been doubling down on its efforts to invent new animal vaccines--opening a 48,000-square-foot research facility near its Indianapolis headquarters, for example, that its animal health division, Elanco, will use for R&D. On the production-animal side of the business, Elanco’s bread and butter until now has been cattle and swine products, but the company is looking to expand into a rapidly growing corner of food production where it has had virtually no presence: aquaculture.


The National Creativity Network (NCN) is pleased to announce the winner of the 2016 USA Creative Business Cup – Kitchology of Germantown, MD. Kitchology ( is the first company to create an integrated social cooking platform for the estimated 160 million people dealing with special diets and the suppliers who sell to them. It allows consumers to overcome the limitations imposed by food restrictions, and makes it easy for like-minded cooks to find each other. Kitchology applies machine learning to nutrition science, profiling and social curation to help the home cook match and modify recipes to satisfy the challenges of food allergies, intolerances, and special diets.  Kitchology enables meal planning based on ingredients previously used and explored, personalized ingredient substitutions, purchasing with intelligent shopping lists, step-by-step cooking, and fosters influencer relationships.


Maryland is a leader in National Institutes of Health funding for biomedical research and in venture capital investment for bioscience-related companies, according to a recent study from the Biotechnology Innovation Organization.

The bioscience industry employs more than 34,000 people in Maryland, and the average annual wage for a bioscience worker in the United States reached $94,543 in 2014, according to the report.


RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for the treatment of patients with MS. The patent covers use of the Company's proprietary molecule Thymosin beta 4 (Tβ4) in a composition for treating or reducing deterioration of, injury or damage to tissue due to MS. The patent expiry is January 13, 2026.


Submit your proposal today for the “Make Your Medical Device Pitch for Kids!” competition. Up to six prizes totaling $250,000 will be awarded to the winning presentations at the 4th Annual Pediatric Surgical Innovation Symposium in Washington, DC hosted by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.


In addition to exploring existing drugs for multiple indications, United Therapeutics (UTHR) has been actively investing in research and development (or R&D) programs involving novel technologies. These are targeted toward pulmonary arterial hypertension (or PAH), cancer, and the orphan disease bronchopulmonary dysplasia (or BPD).


Opinions expressed by Forbes Contributors are their own. Creating a tech invention with global potential is an ambition that many of us harbor but only relatively few are able to actually achieve.

So for the co-creators of a device that monitors newborn baby vital signs and improves their chances of survival in parts of the developing world, the sense of achievement in getting their startup idea off the ground is bolstered further by a feeling of real pride in doing work that could save thousands of lives.


Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:


  • Notice of NCCIH's Participation in PA-16-414 "Innovation Corps (I-Corps) at NIH Program for NIH and CDC Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp)"
    • (NOT-AT-16-003)
    • National Center for Complementary and Integrative Health
  • Notice of Clarification to NHLBI's Policy Regarding Total Years of Support for K24 Funding 
  • Notice of Technical Assistance Webinars for Human Heredity and Health in Africa (H3Africa) FOAs: RFA-RM-011, RFA-RM-012, RFA-RM-013, RFA-RM-014, RFA-RM-16-015, RFA-RM-016, and RFA-RM-017
  • Notice of New Expiration Date for RFA-RM-16-013 "Human Heredity and Health in Africa (H3Africa): Ethical, Legal, and Societal Issues (ELSI) Research Program (U01)"

Requests for Applications: 

  • Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research (R21)

The Next Phase of the FLC Awards is Here - 2017 FLC Awards

The 2017 FLC Awards is now open for nominations. One of the most coveted honors in the technology transfer field, the FLC awards have been presented to over 200 federal laboratories since their inception in 1984. Many of our winning technology transfer efforts have gone on to become products and devices that are indispensable in our daily lives.


D.C.-based Danaher Corp. (NYSE: DHR) is buying California molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) for about $4 billion in cash.

The $53 per share price represents a 54 percent premium on its Friday closing price of $34.42 per share. The deal, expected to close in the fourth quarter, would constitute a sizable addition to Danaher’s $8.2 billion life sciences and medical testing and equipment business.


The Biomedical Research Institute (BRI), founded in Rockville, MD in 1968, is a not-forprofit research institute that emphasizes basic research in schistosomiasis. BRI expanded its subsidiaries in 1985 to include the Association of Entrepreneurial Science (AES), an incubator for startup scientific companies that brings scientists and basic research findings into the realm of commercial markets. AES brings together all the accompanying business skills required for profit making entrepreneurs to bring scientific products and services to the marketplace.

View Flyer


In opening a recent interview with Under Armour (NYSE:UA) founder and CEO Kevin Plank, the commentator described Plank as "next." 

As perhaps the most high-profile member of a cohort of younger CEOs, Plank's overwhelming success in starting and growing Under Armour has become the stuff of business lore. Here are a few of Plank's top quotes on a host of subjects including business, entrepreneurship, and leadership. 


The Maryland Industrial Partnerships (MIPS) Program provides funding for university-based research projects that help Maryland companies develop technology-based products, combining the creative expertise of Maryland’s university faculty with the drive of the state’s entrepreneurs. Up to $100,000 per year is available for each project.

Upcoming Information Sessions

Date: Thursday, September 8
Time: Noon-1 p.m.
Location: Chesapeake Innovation Center, 2288 Blue Water Blvd., Building 300, Suite 310, Odenton, MD 21113

Date: Wednesday, September 14
Time: 3-5 p.m.
Location: Frostburg State University Sustainable Energy Research Facility (SERF), 5 Technology Drive, Frostburg, MD 21532


The Georgetown-based Halcyon Incubator celebrated the commencement of a new cohort on Thursday with another announcement — two years ago, to the day, the incubator itself was launched. In that time, S&R Foundation COO Kate Goodall informed the gathered crowd, the incubator has served 32 ventures, which have raised a collective $10 million in funding and “impacted” 2 million lives around the world.


Startups in the medical device industry are on pace for an uptick in financing, thanks to interest from private market investors, including corporates. We put together a periodic table of medical device companies to highlight promising startups, industry categories, exits, and active investors in the category.


Smart money VCs are on pace to participate in fewer cybersecurity deals through the end of this year, compared to 2015. This year, through Q2’16, the top two dozen smart money VCs participated in nearly 30 cybersecurity funding rounds — deals that totaled $657M in aggregate.


Nope, this isn't a scene out of Free Willy.

It's actually taking place in the Army Bay, New Zealand, where a kayaker casually jumped out of his vessel to hang out with a curious orca on Monday. Tim Stewart is said daring kayaker, who told the NZ Herald he went down to the ocean after he heard of orca sightings in the area.


ExeGi Pharma, LLC announced the launch of the new probiotic formulation, Visbiome™ and Visbiome™ Extra Strength. Visbiome contains the pioneering probiotic blend developed by Professor Claudio De Simone, M.D., Ph.D. (the "De Simone Formulation"), and it has the same strains, in the same concentrations and proportions, and is therapeutically equivalent to the VSL#3®1 probiotic blend produced before January 31, 2016. Visbiome, a medical food, delivers anti-inflammatory probiotic bacteria in high concentrations, normalizing the gut flora and providing sustained relief from symptoms of multiple gastroenterological conditions including ulcerative colitis, chronic pouchitis and irritable bowel syndrome (IBS).


Everyone likes to talk about innovation, but how can you stop simply talking about and start driving real innovation in biotech? We looked at some of the most ground-breaking, silo-busting movers and shakers around to bring you the "Top 5 Ways to Innovate in Biote


Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Christine Brennan, PhD, Principal at Novartis Venture Fund, has joined its Board of Directors effective immediately. Dr. Brennan replaces Florent Gros from Novartis Venture Fund.

“We are extremely pleased to welcome Dr. Brennan to our Board. She has an impressive background in the biopharmaceutical industry, and her experience and guidance will be invaluable as we continue to advance the clinical development of our three drug candidates,” said Bill Enright, President and Chief Executive Officer of Altimmune. “We would also like to thank Mr. Gros for his service to Altimmune over the past year.”


GlaxoSmithKline plc (LSE/NYSE: GSK) today announces a series of agreements with Aspen (JSE: APN) aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.

GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.